Delving into the Latest Updates on Cariprazine hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Cariprazine hydrochloride (JAN/USAN), SYMVENU, cariprazine

+ [10]

Target

5-HT1A receptor x 5-HT2A receptor x D2 receptor

Mechanism

5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists), 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), D2 receptor agonists(Dopamine D2 receptor agonists)

Therapeutic Areas

Other DiseasesCardiovascular DiseasesCongenital Disorders

Active Indication

Depressive Disorder, MajorBipolar and Related DisordersBipolar Disorder+ [7]

Inactive Indication

Chronic schizophreniaGeneralized anxiety disorderMajor depressive disorder, moderate (MDD)+ [2]

Originator Organization

Chemical Works of Gedeon Richter Plc

Active Organization

Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Chemical Works of Gedeon Richter PlcAllergan, Inc.

+ [4]

Inactive Organization

Forest Laboratories, Inc.

Mitsubishi Tanabe Pharma Corp.

Forest Laboratories LLC

+ [2]

Drug Highest PhaseApproved

First Approval Date

US (17 Sep 2015),

Bipolar I disorderSchizophrenia

RegulationSpecial Review Project (CN)

Login to view timeline

Structure

Molecular FormulaC21H33Cl3N4O

InChIKeyGPPJWWMREQHLQT-BHQIMSFRSA-N

CAS Registry1083076-69-0

View All Structures (2)

Bipolar disorder is a common condition that can cause significant disability and risk for suicide. Second generation antipsychotic medications can be used to treat depression in bipolar disorder, yet we do not know how they work. Here, we will use a recently approved medication, cariprazine (Vraylar), to treat participants with bipolar depression. They will have brain imaging with PET scans before and during treatment to understand how the medication may be working. Particularly, we will look at the role of the D3 dopamine receptor.

Start Date01 Oct 2024

Sponsor / Collaborator

The New York State Psychiatric Institute

100 Clinical Results associated with Cariprazine hydrochloride

Login to view more data

100 Translational Medicine associated with Cariprazine hydrochloride

Login to view more data

100 Patents (Medical) associated with Cariprazine hydrochloride

Login to view more data

526

Literatures (Medical) associated with Cariprazine hydrochloride

01 Jan 2025·Journal of Affective Disorders

Adjunctive cariprazine for the treatment of major depressive disorder: Number needed to treat, number needed to harm, and likelihood to be helped or harmed

Article

Author: Kerolous, M ; Kerolous, M. ; Citrome, L ; Reda, I. ; Citrome, L. ; Reda, I

BACKGROUNDThe number needed to treat (NNT) for efficacy and number needed to harm (NNH) for tolerability/safety were evaluated for adjunctive cariprazine in major depressive disorder (MDD).METHODSData were extracted from five randomized, double-blind, placebo-controlled trials of adjunctive cariprazine in MDD. NNTs (response, remission, severity shift) and NNHs (discontinuations due to adverse events [AEs], AEs, laboratory shifts) were determined in dose groupings; likelihood to be helped/harmed (LHH) was calculated.RESULTSNNTs (95 % CI) for adjunctive cariprazine versus placebo were statistically significant at week 6/early termination for response on the Montgomery-Åsberg Depression Rating Scale (MADRS), as defined by a decrease in total score ≥ 50 % (doses ≥ 1 mg/d = 12 [9-21]; 1-2 mg/d = 12 [8-25]; 2-4.5 mg/d = 14 [9-43]) and other response/remission outcomes. NNHs for cariprazine versus placebo were generally ≥ 10 for AEs that were statistically significant; an apparent dose-response was seen for akathisia (lower dose = 24 [17-43]; higher dose = 9 [7-11]). LHHs were ≥ 1 (acceptable benefit/harm ratio) for MADRS total score response versus most important cariprazine AEs in most dose groupings. For response versus discontinuation because of an AE, adjunctive cariprazine 1-2 mg/d had a more favorable response/tolerability profile in indirect comparison with other approved atypical antipsychotics.LIMITATIONSPost hoc analysis; indirect comparisons.CONCLUSIONSPatients receiving adjunctive cariprazine encountered benefits more often than harms; NNT values at week 6/early termination were statistically significant versus placebo on response/remission outcomes across dose groupings from the five pooled studies. Adjunctive cariprazine was well tolerated; NNH values versus placebo were generally > 10, with better akathisia tolerability in the lower-dose range.

31 Dec 2024·Journal of Medical Economics

Healthcare resource utilization and costs associated with first versus subsequent use of cariprazine for bipolar I disorder

Article

Author: Boudreau, Julien ; Parikh, Mousam ; Cutler, Andrew J. ; Germain, Guillaume ; Wade, Sally W. ; Laliberté, François ; MacKnight, Sean D.

AIMSTo evaluate the healthcare resource utilization (HRU) and costs of patients who initiated cariprazine as their first versus subsequent atypical antipsychotic (AA) following a bipolar I disorder (BP-I) diagnosis.METHODSAdults with a BP-I diagnosis (first claim = index), commercial, Medicare Supplemental, or Medicaid insurance, and ≥1 outpatient cariprazine dispensing were identified from Merative MarketScan database. Cohorts included patients who initiated cariprazine as either their first or subsequent AA after initial BP-I diagnosis. Characteristics were balanced between cohorts using inverse probability of treatment weighting (IPTW). Outcomes evaluated post-index included all-cause and mental health (MH)-related HRU (hospitalizations, emergency department [ED] visits, outpatient visits), total healthcare costs (medical + pharmacy), and treatment patterns. HRU and healthcare costs were reported per patient-year (PPY) and compared between cohorts using rate ratios and 95% CIs estimated using nonparametric bootstrap procedures. Treatment patterns were analyzed descriptively, with standardized differences ≥10% considered important.RESULTSAfter IPTW, cohorts included 1,409 patients who initiated cariprazine first and 1,621 patients who initiated cariprazine subsequently; the average (standard deviation, SD) observation period was 678 (373) and 758 (389) days for first and subsequent initiators, respectively. Patients who initiated cariprazine first had 23% fewer all-cause hospitalizations and 28% fewer MH-related hospitalizations PPY (each comparison, p < 0.001). Rates of all-cause and MH-related outpatient visits were significantly lower in patients who initiated cariprazine first versus subsequently (each comparison, p < 0.001), while rates of ED visits were similar. Relative to subsequent initiators, first initiators incurred $2,587 and $2,130 lower all-cause and MH-related total healthcare costs PPY, respectively (each comparison, p < 0.05). Before starting cariprazine, first initiators used fewer BP-I-related medications on average than subsequent initiators (2.6 vs 3.9; standardized difference = 23.9%).LIMITATIONSPotential coding inaccuracies and residual confounding.CONCLUSIONSIn this real-world database analysis, patients with BP-I who initiated cariprazine as their first AA had lower rates of HRU and incurred lower costs than patients who initiated cariprazine as a subsequent AA.

01 Dec 2024·Journal of Affective Disorders

Full-spectrum efficacy of cariprazine across manic and depressive symptoms of bipolar I disorder in patients experiencing mood episodes: Post hoc analysis of pooled randomized controlled trial data

Article

Author: McIntyre, Roger S ; Nguyen, Huy-Binh ; Vieta, Eduard ; Aronin, Lauren C ; Kramer, Ken ; Yu, Jun

INTRODUCTIONPatients with bipolar I disorder may experience mood destabilization or treatment-emergent affective switch (TEAS) from one symptom pole to the other spontaneously or following treatment. Optimal treatment should address symptoms from both poles without precipitating destabilization.METHODSThese were pooled post hoc analyses of data from randomized, double-blind, placebo-controlled studies of cariprazine 3-12 mg/d for bipolar I mania (NCT00488618, NCT01058096, NCT01058668) and cariprazine 1.5 mg/d or 3 mg/d for bipolar I depression (NCT01396447, NCT02670538, NCT02670551). Changes from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at week 6 and Young Mania Rating Scale (YMRS) total score at week 3 were analyzed in each indication using a mixed-effects model for repeated measures. Percentages of patients with increasing levels of endpoint response and TEAS (bipolar mania = MADRS total score ≥ 19; bipolar depression = YMRS score ≥ 16) were determined.RESULTSCariprazine significantly reduced manic and depressive symptoms in patients with bipolar I disorder mood episodes. In patients with a manic episode and up to mild baseline depressive symptoms, cariprazine also significantly reduced depressive symptoms. In patients with a depressive episode and manic symptoms in remission at baseline, numerical reduction (without statistical significance) in YMRS indicated no worsening of mania. In both indications, cariprazine-treated patients had numerically greater response rates (presenting symptom pole) than placebo-treated patients; lower percentages of cariprazine- than placebo-treated patients had TEAS at visits where data were collected.LIMITATIONSPost hoc analysis.CONCLUSIONResults suggested that cariprazine had full-spectrum efficacy across symptoms from both poles in patients with bipolar I disorder mood episodes; TEAS risk was low. Patient-level response suggested that improvement was clinically relevant.

51

News (Medical) associated with Cariprazine hydrochloride

11 Nov 2024

·www.biopharmadive.com

AbbVie’s $9B bet collapses as closely watched schizophrenia drug fails studies

AbbVie lost about $40 billion in market value Monday morning after an experimental drug the company had bet heavily on failed two important clinical trials.The drug, called emraclidine, was developed by Pfizer spinout Cerevel Therapeutics, which AbbVie recently acquired for almost $9 billion. Its one of a new class of brain-balancing medications researchers see as valuable tools for treating a variety of psychiatric conditions. With emraclidine, Cerevel chose schizophrenia as the first target, and over the past couple of years has been running a pair of studies to assess whether the drug can quickly alleviate symptoms of the disorder.AbbVie has now disclosed the studies did not succeed. Three doses of the drug were tested, and neither performed significantly better than a placebo after six weeks of treatment. The trials together enrolled around 750 participants, and evaluated them with a well-known scale used to measure the different symptoms people with schizophrenia experience, from positive ones like excitement and hallucinations to negative ones like emotional withdrawal.“While we are disappointed with the results, we are continuing to analyze the data to determine next steps,“ said Roopal Thakkar, AbbVies chief scientific officer,in the companys statement.The Illinois-based pharmaceutical giant said neuroscience remains one of its key focus areas. Just last month, AbbVie announced plans to spend $1.4 billion buying a startup with an experimental treatment for Alzheimers disease.The company also noted how it gained an entire pipeline of drug programs from the Cerevel acquisition, with multiple clinical-stage and preclinical candidates that complement its existing portfolio of brain medicines. Net revenue from that portfolio, which includes Botox, the antipsychotic Vraylar and the migraine medication Ubrelvy, totaled almost $6.5 billion over the first nine months of this year.One such Cerevel drug, a Parkinsons treatment called tavapadon, defied analyst expectations by succeeding in a late-stage trial earlier this year.Still, AbbVie investors may not see much of a silver lining. Company shares were down more than 12% Monday morning, representing one of the largest single-day dips involving a big pharma stock over the past year.This is disappointing and unexpected, wrote Louise Chen, an analyst at the investment firm Cantor Fitzgerald, in a note to clients.In an earlier, much smaller schizophrenia trial, researchers found two doses of emraclidine each beat a placebo at reducing scores on the same symptoms scale used in the Phase 2 studies.Additionally, emraclidine works in a similar way to Cobenfy, an antipsychotic medication that succeeded in three medium- to large-sized clinical trials before receiving Food and Drug Administration approval in September. Less than three weeks after AbbVie announced its Cerevel acquisition, Bristol Myers Squibb agreed to buy Cobenfys developer, Karuna Therapeutics, for $14 billion.Schizophrenia patients switch medications often, either because they carry side effects like weight gain or because they arent properly controlling the disease. Clinical testing of Cobenfy showed it doesnt cause some of the more challenging side effects seen with other antipsychotics. That, plus Cobenfys ability to act quickly, has led both Bristol Myers and Wall Street analysts to expect billions of dollars in peak annual sales from the drug.Shares of Bristol Myers were up almost 12% late Monday morning.Olivia Brayer, an analyst at Cantor who covers the company, argues that emraclidines failure removes a major overhang for Cobenfy, as its biggest competitive threat in schizophrenia is no longer.The Cerevel acquisition just went up in flames, Brayer wrote in a note to clients, adding that her team has been getting questions about how Bristol Myers stock could move based on the results of AbbVies two studies. But an outright failure wasn't on anyone's bingo card. '

AcquisitionPhase 2Drug ApprovalClinical Result

01 Nov 2024

·www.prnewswire.com

NeuroBlu: New Data Partner and Enterprise SSO Integration

Major expansion of behavioral health data with 940K+ new patient records, enterprise SSO integration, and enhanced analytics tools for deeper research insights. NEW YORK, Nov. 1, 2024 /PRNewswire/ -- Holmusk, a global leader in behavioral health real-world evidence, today announced the release of NeuroBlu Analytics v4.6, a major platform upgrade that combines expanded data coverage, enhanced analytics capabilities, and improved enterprise security through single sign-on (SSO) integration. This latest version of NeuroBlu reflects Holmusk's commitment to advancing behavioral health research and clinical insights by broadening access to quality, structured real-world data and strengthening analytical precision. A new partnership with a leading health provider network has added over 940,000 patient records from the New York City Metro area, increasing NeuroBlu's U.S. coverage to nearly 5 million patient encounters annually. This expanded dataset, integrated with Datavant tokenization, now enables pharmaceutical researchers to link granular psychiatric assessment data with claims outcomes, providing unprecedented insights into real-world treatment patterns and outcomes. "The most recent updates to NeuroBlu mark a transformative step forward in our ability to link clinical data with claims, unlocking insights that will drive better research and patient outcomes," said Holmusk CEO Nawal Roy. "With this powerful update to our new dataset, our platform enables researchers to make evidence-driven decisions in trial design, patient care, and health economics." Major Dataset Expansion The latest partnership expands NeuroBlu's reach into the Northeastern United States, adding comprehensive data for over 436,000 patients with anxiety disorders and 158,000 with major depressive disorder. Coverage includes key psychiatric medications, with insights into treatment sequences and real-world usage patterns. This unique dataset provides: Extensive Medication Data: 94% of patients have detailed medication history, covering commonly prescribed psychiatric medications like Vraylar (3,600+ patients) and Rexulti (2,200+ patients). Robust Geographic Representation: Coverage across NY, NJ, PA, CT, and FL enhances regional insights and relevance. Longitudinal Data and Vitals Tracking: Patients' treatment patterns and outcomes are tracked over time, offering a detailed view of treatment pathways and patient journeys. Claims Data Integration Through the integration of Datavant tokenization, NeuroBlu 4.6 enables the linkage of detailed psychiatric assessments with claims data, creating new possibilities for pharmaceutical research and health outcomes research. Key benefits include: Clinical Trial Optimization: Linking scales like PSS-3, PHQ-9, and GAD-7 with claims data enables researchers to optimize clinical trial design, track real-world treatment patterns across 940,000+ patients, and develop synthetic control arms. Evidence Generation: Linked datasets allow researchers to validate clinical endpoints, analyze medication adherence, and assess treatment discontinuation in real-world settings. These insights support augmentation strategies, examine concomitant medication use, and analyze healthcare utilization across diverse patient subgroups. Value Demonstration and HEOR Support: NeuroBlu's data-linking capabilities enable health economics and outcomes research (HEOR) by connecting clinical outcomes with cost data, examining treatment sequences, and enabling comparative effectiveness research. Long-term safety and effectiveness can now be tracked through linked datasets, strengthening insights into the value of mental health interventions. Enterprise-Grade Security with SSO Integration With the release of NeuroBlu Analytics v4.6, Holmusk introduces enterprise-grade single sign-on (SSO) integration, significantly enhancing security and access management for users. This new SSO functionality allows enterprise clients to securely and seamlessly access the NeuroBlu platform, meeting high-security standards and making user management more efficient for larger teams and organizations. Additionally, NeuroBlu 4.6 offers new SQL templates, allowing researchers to accelerate their data workflows, along with updated R and Python libraries featuring improved documentation for streamlined data integration. Together, these upgrades support researchers in extracting deeper insights with ease and efficiency, advancing NeuroBlu's mission to set new standards for security, usability, and innovation in behavioral health research. About Holmusk Holmusk is on a mission to harness real-world data to transform research and behavioral health care. Combining leading behavioral health data with AI-powered analytics and digital solutions designed to address the most pressing challenges in behavioral health, Holmusk is advancing the frontier of evidence generation and fueling innovation. Holmusk is headquartered in New York, with four additional offices worldwide. For more information, please visit . SOURCE Holmusk WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

29 Oct 2024

·www.echemi.com

AbbVie Spends $1.4 Billion to Acquire Aliada, Betting on Uncertain Alzheimer’s Treatment Prospects, Stock Price Only Slightly Rises by 1%

AbbVie announced on Monday that it would buy Aliada Therapeutics for $1.4 billion in cash, a bet on an experimental Alzheimer's treatment that is in early development. The acquisition pitted AbbVie, which has a market capitalization of as much as $330 billion, against at least three other pharmaceutical companies interested in Aliada, according to insiders. Shares of AbbVie were up 1% at Monday's close. Competition for Aliada's privately held Alzheimer's drug candidate has driven up the deal price, according to people familiar with the matter, showing that despite the historical regulatory risks associated with drugs for the mentally wasting disease, there are still many pharmaceutical companies willing to invest early in such treatments. Two similar therapies that reduce toxic amyloid plaques in the brain were recently approved in the U.S. after decades of failure. AbbVie is aggressively expanding its portfolio of neuroscience products as sales of its top-selling arthritis drug Humira fell 33%. Humira was once the world's best-selling drug, but now faces competition from several cheaper biosimilars. To further strengthen its pipeline, AbbVie has already acquired neuroscience drug developer Cerevel Therapeutics and cancer drug developer ImmunoGen earlier this year in deals totaling about $19 billion. At least 11 monkeys have died at Hong Kong Zoo in the past week. Abbvie said Aliada's antibody therapy, ALIA-1758, could be the best of its kind. ALIA-1758 uses a protein in the blood called transferrin to carry iron to transport an antibody that degrades and eliminates amyloid plaques - sticky protein deposits in the brain that are a sign of Alzheimer's disease. "Many promising CNS targeted therapies fail to enter late-stage trials because they cannot cross the blood-brain barrier," said Michael Ryan, Aliada's medical director. "Our [drug delivery] platform directly addresses this challenge, effectively delivering targeted drugs and potentially transforming the way we treat neurological diseases," he added. With the approval of Biogen (BIIB.O) and Eisai (4523.T) (Leqembi) and Lilly (Lill.N) (Kisunla), amyloid plaques are confirmed as a therapeutic target, BMO analyst Evan Seigerman said. But Alzheimer's disease remains a high-risk indication. The number of people with Alzheimer's disease is expected to double from 6.9 million in 2020 to nearly 14 million by 2060, according to the CDC. Abbvie expects to close the deal by the end of this year. Abbvie's neuroscience therapies, which include botox and bipolar disorder drug Vraylar, brought in $4.13 billion in sales in the first half of 2024, up 15.3% year over year.

AcquisitionDrug Approval

100 Deals associated with Cariprazine hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09876	Cariprazine hydrochloride	N05AX15	DB06016

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Depressive Disorder, Major	US	AbbVie, Inc.	16 Dec 2022
Bipolar and Related Disorders	CA	Gedeon Richter (UK) Ltd.	27 Apr 2022
Bipolar Disorder	CA	Allergan, Inc.	22 Apr 2022
Bipolar I disorder	US	AbbVie, Inc.	17 Sep 2015
Schizophrenia	US	AbbVie, Inc.	17 Sep 2015

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bipolar I disorder	Phase 2	RU	Gedeon Richter (UK) Ltd.	01 Feb 2010
Bipolar I disorder	Phase 2	HR	Forest Laboratories LLC	01 Feb 2010
Bipolar I disorder	Phase 2	RO	Forest Laboratories LLC	01 Feb 2010
Bipolar I disorder	Phase 2	IN	Gedeon Richter (UK) Ltd.	01 Feb 2010
Bipolar I disorder	Phase 1	RS	Gedeon Richter (UK) Ltd.	01 Feb 2010
Bipolar I disorder	Phase 1	US	Gedeon Richter (UK) Ltd.	01 Feb 2010
Bipolar I disorder	Phase 1	IN	Forest Laboratories, Inc.	01 Feb 2010
Bipolar I disorder	Phase 1	UA	Gedeon Richter (UK) Ltd.	01 Feb 2010
Bipolar I disorder	Phase 1	RO	Gedeon Richter (UK) Ltd.	01 Feb 2010
Bipolar I disorder	Discovery	HR	Gedeon Richter (UK) Ltd.	01 Feb 2010

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NEWS Manual	Not Applicable	Schizophrenia	116	cariprazine (women outpatients)	rqvnnyudcq(eigdwdtfjk) = There was a significant change from baseline in women to week 16 in the SAND scores: negative symptoms decreased by 6.2, positive symptoms decreased with 1.0, which is a remarkable, combined 7.2 drop. uujzdpgykx (yuwtfybste )	-	18 Oct 2023
NCT03573297 (CTgov)	Phase 3	Mania \| Depressive Disorder \| Bipolar I disorder	901	placebo (Double-Blind Placebo QD)	hsklhekyax(ieqjubqzrf) = alwlrrgkxk vkemyodygv (oawwlcprhm, agvmsigbgz - ompwihhjpl) View more	-	28 Sep 2023
				Cariprazine (Double-Blind Cariprazine 1.5 mg QD)	hsklhekyax(ieqjubqzrf) = nvtphdncxp vkemyodygv (oawwlcprhm, fsnltfqfgz - lbuswlqtpb) View more
Pubmed	Phase 3	Depressive Disorder, Major	751	Placebo	(ufxnqoxhfe) = ufiklucnnr ctizommzaz (dbpsmwohud )	Positive	15 Feb 2023
				Cariprazine 1.5 mg/day	(ufxnqoxhfe) = qcowdxtnlw ctizommzaz (dbpsmwohud )
NCT03738215 (CTgov)	Phase 3	Major depressive disorder, moderate (MDD) \| Depressive Disorder, Major	759	Placebo (Placebo + ADT)	twzqwszdfj(xbwhrlxkod) = rttkxwowjm nkbuxixdqy (vrgrhfukva, ktklpazhwp - ogcccrhtzg) View more	-	25 Oct 2022
				Cariprazine (Cariprazine 1.5 mg/Day + ADT)	twzqwszdfj(xbwhrlxkod) = pfvjhwqbom nkbuxixdqy (vrgrhfukva, nelniogatt - zdudyvlxvn) View more
NCT03739203 (CTgov)	Phase 3	Major depressive disorder, moderate (MDD) \| Depressive Disorder, Major	752	Placebo+Antidepressant Therapy (ADT) (Placebo + ADT)	rfargomamq(qwvxpwvbyy) = amidsfnucf zmjxswqrjv (qqrfhatfwn, uztgwdfaux - rnjhmmdpxy) View more	-	21 Sep 2022
				Antidepressant Therapy (ADT)+Cariprazine (Cariprazine 1.5 mg/Day + ADT)	rfargomamq(qwvxpwvbyy) = nhtceinvsp zmjxswqrjv (qqrfhatfwn, fhyegpbhfb - hijzefktfo) View more
NCT03593213 (CTgov)	Phase 3	Schizophrenia	587	Placebo (Placebo (Double-blind Treatment Period))	pzyernzzhl(xegmktvuwe) = trljtsmshg oskphudycb (rjfzukhszk, mktqxcyojt - zsaoyhfzhf) View more	-	08 Mar 2022
				Cariprazine (Cariprazine 3.0 mg/Day (Double-blind Treatment Period))	pzyernzzhl(xegmktvuwe) = mnpdakaukd oskphudycb (rjfzukhszk, qnwuqdfhxg - isteqgkfts) View more
NCT01625897 (CTgov)	Phase 2/3	Schizophrenia	125	MP-214 (MP-214 1.5-9mg)	nfdiddqnju(cnxzytoayw) = olcrzoekje slirxgesaw (ysrunfcehu, sbdnsxhhay - nztvhruwjh) View more	-	13 Apr 2021
				Risperidone (Risperidone 2-12mg)	nfdiddqnju(cnxzytoayw) = tztrcyhymo slirxgesaw (ysrunfcehu, ipkktrvslh - wfkzjaxldr) View more
NCT01626885 (CTgov)	Phase 2/3	Schizophrenia	42	MP-214	ftyqqagnul(bmgulcdbrx) = xoafvzaayl phesbumugy (ixmrtltolh, jvjehmatyt - vlsmkuaort) View more	-	13 Apr 2021
NCT01626872 (CTgov)	Phase 2/3	Schizophrenia	254	MP-214 3mg (MP-214 3mg)	rvpvoanoxx(xxkvuserrn) = dvcfrbmaso ujuqabcqyt (fwehxlxsmt, hdbgwjtoyk - vajceapeab) View more	-	12 Apr 2021
				MP-214 6mg (MP-214 6mg)	rvpvoanoxx(xxkvuserrn) = pqdzrkgzuf ujuqabcqyt (fwehxlxsmt, itdbdilzrx - xtuetbpaio) View more
NCT01626859 (CTgov)	Phase 2/3	Schizophrenia	38	MP-214 3mg (MP-214 3mg)	uyojuzfpqw(mndwbuglpg) = zuooomewim wsjlwduygn (yeybtotite, cudhkdhnhq - urasxycfmn) View more	-	12 Apr 2021
				MP-214 6mg (MP-214 6mg)	uyojuzfpqw(mndwbuglpg) = dnbuswqxdw wsjlwduygn (yeybtotite, gwxfdkcdff - fendqcdvxf) View more